Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | HM43239 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HM43239 | HM-43239|HM 43239 | FLT3 Inhibitor 57 | HM43239 inhibits both wild-type and mutant FLT3, resulting in decreased activation of downstream signaling, and potentially leading to increased apoptosis and decreased proliferation of tumor cells (Cancer Res 2019;79(13 Suppl):Abstract nr 1293). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins FLT3 F691L | hematologic cancer | predicted - sensitive | HM43239 | Preclinical | Actionable | In a preclinical study, HM43239 treatment inhibited transformed cells expressing FLT3 ITD and F691L in cell culture (Cancer Res 2019;79(13 Suppl):Abstract nr 1293). | detail... |
FLT3 exon 14 ins FLT3 D835Y | hematologic cancer | predicted - sensitive | HM43239 | Preclinical | Actionable | In a preclinical study, HM43239 treatment inhibited transformed cells expressing FLT3 ITD and D835Y in cell culture (Cancer Res 2019;79(13 Suppl):Abstract nr 1293). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03850574 | Phase Ib/II | HM43239 | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 1 |